Announcement PDF ASX Announcement 16 November 2023 Bell Potter Healthcare Conference 2023 Microba Life Sciences Limited (ASX: MAP) (“Microba”), is pleased to announce that it will present at the Bell Potter Healthcare Conference today, Thursday November 16 2023, at 12:00pm – 12:25pm AEDT (Sydney/Melbourne) / 11:00am — 11:25am (Brisbane). Microba CEO, Dr Luke Reid will deliver the presentation. A copy of the presentation is attached to this announcement. Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: https://extraconnect.co/bell-potter-healthcare-2023-ext/ This announcement has been authorised for release by the Chairman and Chief Executive Officer. For further information, please contact: Dr Luke Reid Chief Executive Officer E: Luke.Reid@microba.com Investor / Media Relations E: investor@microba.com W: https://ir.microba.com/ Join our Investor Mailing List About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit: www.microba.com Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia T: 1300 974 621 E: investor@microba.com W: microba.com Transforming health through the human microbiome Bell Potter Healthcare Conference 2023 November 2023 Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above. Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws. Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended. Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance. Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright. Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation. 2 Two core business segments driven by a proprietary databank Services Databank Therapeutics Proprietary databank Customer Testing Microba provides testing and data analysis for a fee to clinicians, consumers and research customers Data Health Data Biome Data Driving discovery of novel therapeutic leads Insights Novel Therapies Data-driven therapeutics platform developing novel monoclonal microbial cell therapies 3 Company Snapshot Continuous YoY revenue growth over 5 years of operations Partnerships with market leaders incl. Sonic Healthcare (ASX: SHL), Ginkgo Bioworks (NYSE: DNA), SYNLAB (GR:SYAB) + more Large, unique, proprietary microbiome databank 3 key therapeutic programs with lead IBD drug candidate in Phase I trial read out expected Dec 23 World-leading technology in the emerging and rapidly growing US$4.9 billion microbiome sector1 Globally leading microbiome expertise complemented by drug discovery experts including Prof. Ian Frazer 1 Frost & Sullivan market report – Growth Opportunities in Human Microbiome Market Forecast to 2023 – Prepared November 2019 4 Microbiome Services Driving global revenues and data growth 5 | Q1 FY24 Highlights – Testing Services MetaPanel progressing to launch in Australia 65% Growth in personal testing Execution of Microba’s Testing Services growth strategy saw 62% and 72% yoy revenue growth for domestic and international Personal Testing respectively. continued growth in uptake of MetaXplore™ in Australia with 33% growth in tests sold between June and September. Q1 FY24 Revenue versus pcp (A$m) 15% 1.1 0.9 Personal Research 0.5 0.4 0.8 0.3 Q1 FY23 Q1 FY24 Microba’s advanced infectious disease testing technology MetaPanel™ progressing to launch in Australia with Sonic Healthcare (ASX: SHL) targeting first test delivery before end of Q2 FY24. Further European expansion New agreement executed with SYNLAB to deliver Microba’s testing into Norway, Serbia and additional European countries. +65% -42% $26 million in cash or equivalents as at 30 September 2023. $6 million FY23 R&D tax expected. 6 Advanced microbiome testing addressing large markets in healthcare Addressable Healthcare Markets Gastrointestinal disorders Gastrointestinal infection Is the microbiome contributing to the patients DGBI and how can they manage? Does the patient have a pathogen and how can I selectively treat it? 150M est. addressable patients worldwide1 16M est. addressable patients worldwide2 Well established out of pocket private pay market Well established hospital direct-bill and path to reimbursement 1Estimated based on the prevalence of specific Disorders of the Gut-Brain Interaction across 26 countries (Av prevalence of 32.8% DOI: 10.1111/nmo.14594), and the proportion regularly seeking medical support with one or more doctor visit per month (Average 15.4% - DOI: 10.1053/j.gastro.2020.04.014) 2 Estimated based on the global number of immuno-compromised patients and other patients at high risk for gastrointestinal infection (>8.1m chemotherapy treated solid tumor cancer patients and >1.1m haematological cancer patients DOI::https://doi.org/10.1016/S1470-2045(19)30163-9), (>3m dialysis patients DOI: 10.1038/s41581-022-00542-7), (>140k Organ Transplant patients per year https://www.transplant-observatory.org/), (>3.5m long stay ICU patients – estimate based on data from https://ourworldindata.org/grapher/intensive-care-beds-per-100000 ) 7 Significant international distribution Partners provides access into 35 countries with 16 now operational Strategic acquisition unlocking a geographical base and laboratory in the UK, supporting the next phase of Microba’s international growth strategy. Operating Team and/or Laboratory Centre's Contracted partner/s operational Access via current distribution partners 8 | UK Strategic Aquisition 9 | Taking a leading position in the UK market Invivo together with our Sonic Healthcare partnership provides Microba with deep access to the entire UK healthcare market spanning private practice and the public NHS environment UK TARGET HEALTHCARE MARKET 2k Capturing the integrative healthcare market Driving broad adoption into general practice, specialists & hospitals 8k • Leading microbiome testing company targeting integrative healthcare practitioners >49k • Est. 10k integrative healthcare professionals in the UK* 10k • Growth market – more people seeking out private health services in the UK healthcare professionals • Leading medical diagnostics company in the UK • Preparing to deliver MetaXplore and MetaPanel • Addressable UK target practitioners: - 25k General Practitioners^ - 10k Clinical dieticians^ - 4.7k Specialists positioned to adopt microbiome testing^ 25k 5k • Customers positioned to adopt Microba’s MetaXplore testing GP Specialists Dieticians Nutritionist Integrative GP * British Association for Nutrition and Lifestyle Medicine has 3,500 practicing members, Association of Nutrition has 4,400 nutritionist members, and there are an estimated 2,000 practicing integrative Medical Doctors in the UK 10 on file. ^ 4,702 specialists covering Infectious Disease, Gastroenterology, Clinical Oncology, Transplant, Nephrology and Intensive care. 27,246 General Practice Doctors minus 2,000 estimated integrative General Practitioners. Approximately 10,000 registered dieticians. References | Invivo acquisition provides strong UK customer base FY23 Key metrics 7,300+ tests sold Engaged customer base 17% penetration into the UK integrative healthcare professional market and well positioned to accelerate growth 1,700+ ordering HCPs^ 94% of revenue driven by repeat customers# 51% A$8.9m revenue* Gross Profit Margin 10,000+ sample biobank Remaining market Invivo customer Invivo engaged lead * *AUDGBP FX conversion rate of 0.52, Invivo has a financial year-end of 30 March, this number is pro-forma to Australian financial year-end, 30 June. # 55.5% of healthcare practitioners (HCP) ordered more than once in the last twelve months, these repeat customers are responsible for 94% of HCP revenue ^ HCPs is an abbreviation of Healthcare Professionals 11 | Strengthening Invivo's position in GI microbiome testing A platform for UK market entry and growth of Microba’s MetaXplore™ test 79% of Invivo’s testing revenue is through their GI products*. “From our leading position in market, we expect Microba’s world leading MetaXplore™ will become the most favoured microbiome test for healthcare professionals in the UK” Debbie Cotton – Head of Clinical Innovation, Invivo • Current leading GI testing product for UK healthcare professionals • Next generation advanced GI test using Microba’s world leading metagenomic technology • Featuring 7 host markers, 62 microbial markers • Microbiome analysis via multiplex PCR • Includes 7 host markers, 28,000 microbial markers, 19 microbiome functions • Offers static PDF reports • Offers both static PDF and interactive digital reports. 19% growth in GI testing revenue in FY23^ 12 Microbiome Therapeutics Developing novel monoclonal microbial cell therapies 13 | Q1 FY24 Highlights – Therapeutics Inflammatory Bowel Disease Program MAP315 Phase I all patients dosed. Positive MOA data generated. Dosing and all patient visits successfully completed. Preliminary blinded data indicates that MAP315 is well tolerated. Multi-modal mechanism of action (MOA) data generated for MAP315. Results remain on track for Dec 2023. Immuno-Oncology Program Confirmed potent anti-tumour activity. Second mouse model demonstrated again that Microba’s therapeutic leads significantly reduce tumour burden. Further, immunological studies demonstrated activity consistent with induction of a specific and targeted immune response. Additional animal studies and immune profiling experiments are continuing with further data expected in Q2 FY24. Autoimmune Disease Program Primary screening >50% complete. Microba have transferred all target strains to Ginkgo and Stage 1 activity screens are now more than 50% complete. It is expected that Stage 1 activity screening is completed, and data available by the end of Q2 FY24. Stage 2 screening to complete in H1 2024. 14 A therapeutic revolution. Novel, precision microbiome therapeutics Precision Microbiome Therapeutics    Precision microbiome analysis platform delivering unparalleled accuracy, coverage & depth. Data driven discovery platform utilising one of the worlds most advanced & highly curated microbiome datasets. Next generation approach to microbiome drug development identifying single keystone species and their biology to develop Live Biotherapeutics. Microba Partners Innovative Pipeline  Excellent safety profile  Scalable GMP manufacturing for high dose oral delivery  Potent and novel biology mediated by Live Biotherapeutic strategy Strong Corporate Profile  US Pharmaceutical Executive leadership  Technically robust multi-disciplinary team  Global partners Team Experience 15 Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies Population testing Identify groups Healthy AI & Advanced Biostatistics Monoclonal microbial drug lead Disease Proprietary microbiome databank driving multiple therapeutic opportunities through a capital light platform Disease Models Orally administered, healthy human donor derived, monoclonal bacterial cell drug opportunity 16 | Rapid progress tapping the therapeutic potential of the human microbiome for major chronic diseases Inflammatory Bowel Disease Immuno-Oncology Program Autoimmune Diseases PHASE I IN PROCESS PRECLINICAL SCREENING Recently Completed Recently Completed Recently Completed  Phase I HREC approval  Leads discovered  Program commenced  cGMP manufacturing complete  Leads isolated  Strains provided to Ginkgo  Phase I trial commenced  First animal model results  First in vitro screening results Upcoming milestones Upcoming milestones Upcoming milestones • Immunological pre-clinical results • Stage 1 activity screening complete • Phase I complete • Lead candidate selection • Stage 2 activity screening complete  Phase I participant dosing complete 17 The start of a therapeutic revolution 1 First Generation Fecal Doner Derived 2 Second Generation Bacterial Consortia FDA approval Nov 30 2022 Feacal doner derived enema drug product Vedanta Biosciences Vedanta Biosciences Raises $106.5M in Funding FDA approval April 27 2023 Feacal doner derived oral capsule drug product SER-155 Phase 1b showing engraftment reduction in pathogens 3 Next Generation Single Strain & Small Molecule MAP315 Phase I – Ongoing, readout expected December 2023 18 | Executing towards pharmaceutical out-licensing transactions Recent IBD and microbiome deals Licensee / Acquiror Licensor / Target Date Type Deal size Indication / clinical stage Apr 2023 Acquisition Total deal size: US$10.8b Ulcerative Colitis (phase 2) Crohn’s disease (phase 2A) Autoimmune diseases (phase I or pre clinical) July 2022 R&D collaboration and license agreement Total deal size: Undisclosed Upfront: €40m Sales / regulatory milestones: Undisclosed Food allergies and IBD (pre clinical) Mar 2022 Acquisition Total deal size: US$6.7b Ulcerative Colitis (FDA Approved, 2023), Crohn’s disease (phase2/3), Atopic dermatitis (phase 2 complete) Nov 2021 R&D collaboration and license agreement Total deal size: US$605m Upfront: US$15m Additional payments: US$590m IBD (Discovery) Jul 2021 Licensing agreement in US/Canada Total deal size: US$525m Upfront: US$175m Sales / regulatory milestones: Up to US$225m Recurrent Clostridioides difficile infection (Phase 3) https://www.merck.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences-inc/ https://www.enterome.com/news-events/enterome-signs-major-strategic-rd-collaboration-with-nestle-health-science-to-develop-and-commercialize-new-allermimics-and-endomimics-immunotherapies-for-food-allergies-and-inflamm/ https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals http://novomebio.com/wp-content/uploads/2021/11/Novome-and-Genentech-Enter-into-Strategic-Collaboration.pdf https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-nestle-health-science-announce-ser-109-co 19 Outlook 20 Upcoming Milestones for 2023 2023 JAN – MAR 2023 APR - JUN Services Services New healthcare product full launch New international distribution deals Services Therapeutics - IBD MAP 315 program New international distribution deals Therapeutics - IBD MAP 315 program Phase I HREC Submission Therapeutics - IBD MAP 315 program FDA Pre-IND meeting outcome HREC Approval for Phase I trial Therapeutics - IBD MAP 315 program GMP manufacture complete Phase I Therapeutics - IBD MAP 315 program Phase I trial commencement 2023 JUL - DEC Services New country expansion Services First Sonic partners operational Therapeutics - IBD MAP 315 program Phase I participant dosing complete Therapeutics - IBD MAP 315 program Phase I complete Therapeutics - IO Program Therapeutics – IO Program Therapeutics – Autoimmune Program Therapeutics - Autoimmune Program Pre-clinical results First in vitro screening results Immunological pre-clinical results Stage 1 activity screening complete 21 Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Pasquale Rombola Level 10, 324 Queen Street Brisbane QLD Australia pasquale.rombola@microba.com Laboratory Chairman Princess Alexandra Hospital Woolloongabba QLD Australia